Author:
Savage Sara R.,Wang Yuefan,Chen Lijun,Jewell Scott,Newton Chelsea,Dou Yongchao,Li Qing Kay,Bathe Oliver F.,Robles Ana I.,Omenn Gilbert S.,Thiagarajan Mathangi,Zhang Hui,Hostetter Galen,Zhang Bing
Abstract
Abstract
Background
Omics characterization of pancreatic adenocarcinoma tissue is complicated by the highly heterogeneous and mixed populations of cells. We evaluate the feasibility and potential benefit of using a coring method to enrich specific regions from bulk tissue and then perform proteogenomic analyses.
Methods
We used the Biopsy Trifecta Extraction (BioTExt) technique to isolate cores of epithelial-enriched and stroma-enriched tissue from pancreatic tumor and adjacent tissue blocks. Histology was assessed at multiple depths throughout each core. DNA sequencing, RNA sequencing, and proteomics were performed on the cored and bulk tissue samples. Supervised and unsupervised analyses were performed based on integrated molecular and histology data.
Results
Tissue cores had mixed cell composition at varying depths throughout. Average cell type percentages assessed by histology throughout the core were better associated with KRAS variant allele frequencies than standard histology assessment of the cut surface. Clustering based on serial histology data separated the cores into three groups with enrichment of neoplastic epithelium, stroma, and acinar cells, respectively. Using this classification, tumor overexpressed proteins identified in bulk tissue analysis were assigned into epithelial- or stroma-specific categories, which revealed novel epithelial-specific tumor overexpressed proteins.
Conclusions
Our study demonstrates the feasibility of multi-omics data generation from tissue cores, the necessity of interval H&E stains in serial histology sections, and the utility of coring to improve analysis over bulk tissue data.
Funder
National Cancer Institute,United States
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. American Cancer Society. Cancer facts and figures 2022. Atlanta: American Cancer Society; 2022. p. 80.
2. Tang K, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16:28–37.
3. Cancer of the pancreas—cancer stat facts. SEER. 2023. https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed on 14 Feb 2023.
4. Cros J, Raffenne J, Couvelard A, Poté N. Tumor heterogeneity in pancreatic adenocarcinoma. Pathobiology. 2018;85:64–71.
5. Cao L, Huang C, Zhou DC, Hu Y, Lih TM, Savage SR, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184:5031-5052.e26.